论文部分内容阅读
目的:探究ZEB1的表达与三阴性乳腺癌(TNBC)临床病理及预后的关系。方法:收集我院75例三阴性乳腺癌患者的肿瘤组织标本及临床病理资料,免疫组化法分析肿瘤组织中ZEB1的表达情况以及其表达与临床病理特征及预后之间的关系。结果:免疫组化结果显示75例标本中ZEB1阳性表达14例,阳性率18.7%。ZEB1的表达与患者的年龄、肿瘤分期、组织学分级、是否有淋巴结转移以及p53的表达情况无关(P>0.05),与组织学类型及Ki-67增殖指数有关(P<0.05)。Kaplan-Meier生存曲线分析患者的DFS显示,ZEB1的表达与TNBC患者的预后成负相关(P<0.05)。结论:在TNBC中,ZEB1的表达与肿瘤的组织类型、浸润、转移及患者预后密切相关,其表达可以作为一种潜在的临床病理指标来评价TNBC的恶性程度与预后。
Objective: To investigate the relationship between the expression of ZEB1 and the clinicopathology and prognosis of triple negative breast cancer (TNBC). Methods: Tumor specimens and clinicopathological data of 75 patients with triple-negative breast cancer were collected. The expression of ZEB1 in tumor tissue and its relationship with clinicopathological features and prognosis were analyzed by immunohistochemistry. Results: The results of immunohistochemistry showed that ZEB1 positive expression in 75 specimens of 14 cases, the positive rate of 18.7%. The expression of ZEB1 was not related with age, tumor stage, histological grade, lymph node metastasis and p53 expression (P> 0.05), but also with histological type and Ki-67 proliferation index (P <0.05). Kaplan-Meier survival curve analysis of patients with DFS showed that the expression of ZEB1 was negatively correlated with the prognosis of patients with TNBC (P <0.05). Conclusion: The expression of ZEB1 in TNBC is closely related to the type, infiltration, metastasis and prognosis of the patients. The expression of ZEB1 can be used as a potential clinical and pathological index to evaluate the malignancy and prognosis of TNBC.